JMJD6 (D3O3N) Rabbit mAb #60602
- WB
- IHC
Supporting Data
| REACTIVITY | H Mk |
| SENSITIVITY | Endogenous |
| MW (kDa) | 46, 49 |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
- IHC-Immunohistochemistry
Species Cross-Reactivity Key:
- H-Human
- Mk-Monkey
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunohistochemistry (Paraffin) | 1:3200 |
Storage
Protocol
Specificity / Sensitivity
Species Reactivity:
Source / Purification
Background
Although mutations in the sequence of JMJD6 have not been observed in cancer, its overexpression is identified in various cancers and is associated with aggressive disease progression and poor prognosis (10). This holds true for certain types of colon (3), lung (11), and breast cancers (12, 13). Based on these findings, JMJD6 has drawn interest as a potential therapeutic target and biomarker for certain cancer types.
- Kwok, J. et al. (2017) Front Genet 8, 32.
- Webby, C.J. et al. (2009) Science 325, 90-3.
- Wang, F. et al. (2014) PLoS Biol 12, e1001819.
- Hahn, P. et al. (2010) PLoS One 5, e13769.
- Liu, W. et al. (2013) Cell 155, 1581-95.
- Poulard, C. et al. (2014) PLoS One 9, e87982.
- Gao, W.W. et al. (2015) Proc Natl Acad Sci U S A 112, E3327-36.
- Lawrence, P. et al. (2014) Virology 452-453, 1-11.
- Tikhanovich, I. et al. (2015) J Biol Chem 290, 22236-49.
- Vangimalla, S.S. et al. (2017) Biomolecules 7, .
- Zhang, J. et al. (2013) Tumour Biol 34, 2397-401.
- Lee, Y.F. et al. (2012) Breast Cancer Res 14, R85.
- Poulard, C. et al. (2015) PLoS One 10, e0126181.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.